Shares of Inspire Medical Systems (NYSE:INSP) Inc. experienced a significant surge, climbing up to 12% following the company's announcement that it anticipates weight-loss medications to expand the number of eligible candidates for its sleep apnea treatment device.
The medical-device maker's CEO, Timothy P. Herbert, addressed the Morgan Stanley Healthcare Conference, highlighting the issue that many patients are currently ineligible for Inspire therapy due to their high Body Mass Index (BMI).
Herbert explained that the company is actively engaging with physicians to increase awareness about the benefits of GLP-1 medications. These drugs are intended to aid in weight loss, which can subsequently decrease the severity of obstructive sleep apnea, making more patients suitable for the company's implant.
He emphasized that while GLP-1 drugs are not directly aimed at treating obstructive sleep apnea, they can play a supportive role in managing the condition by helping patients reduce their BMI.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.